Trial · NCT06855433
Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment
NCT06855433, Phase 2, Recruiting, Brigham and Women's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment. Trials, record NCT06855433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06855433
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment
- NCT number
- NCT06855433
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- CPPD - Calcium Pyrophosphate Deposition Disease
- Interventions
- Colchicine Pill, Placebo
- First posted
- 2025-03-03
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interleukin 18 (IL-18) | Baseline and Week 24 | Serum IL-18 |
| Secondary | Serum IL-1b | Baseline and Week 24 | Serum IL-1b |
| Secondary | Serum IL-17A | Baseline and Week 24 | Serum IL-17A |
| Secondary | High-sensitivity C-reactive protein (hsCRP) | Baseline and Week 24 | High-sensitivity C-reactive protein in blood |
| Secondary | IL-1b gene signature expression in PBMCs | Baseline and Week 24 | Expression of a panel of genes involved in IL-1b production or signaling, as percentage of total gene expression per cell |
| Secondary | Immune cell population frequencies | Baseline and Week 24 | Immune cell clusters among PBMCs |
| Secondary | Pain visual analog scale (pain VAS) | Baseline, Week 12, Week 24 | Severity of pain from CPPD disease/pseudogout, both at rest and with activity, in the past 7 days (range 0-100mm, with 0 indicating no pain) |
| Secondary | Brief Pain Inventory (Short Form) | Baseline, Week 12, Week 24 | Brief Pain Inventory includes two sub-scores: Pain Severity Score (range 0-10, with 0 indicating no pain in the past 24 hours) and Pain Interference Score (range 0-10, with 0 indicating no interference in the past 24 hours) |
| Secondary | Pain in the past week (PEG [pain intensity [P], interference with enjoyment of life [E], and interference with general activity [G]) | Baseline, Week 12, Week 24 | 3 question instrument, range 0-10, with 0 indicating no pain and no interference in the past week |
| Secondary | Patient Reported Outcome Measurement Information System (PROMIS)-Physical Function | Baseline, Week 12, Week 24 | PROMIS-Physical Function Short Form 10a (T-score range 0-100, with higher scores indicating better physical function) |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06855433
GET https://conductscience.org/api/trials/v1/NCT06855433/registered